viewKazia Therapeutics Ltd

Kazia Therapeutics a top-10 finalist in ANZLF Trans-Tasman Innovation and Growth Awards

The four award winners will be announced at a dinner in Auckland, New Zealand, next Thursday, September 12, presented by NZ Prime Minister Jacinta Arden.

Kazia Therapeutics Ltd - Kazia Therapeutics a top-10 finalist in the ANZLF Trans-Tasman Innovation and Growth Awards
The judges are looking for companies that exhibit collaboration, growth, talent and a unique funding approach

Kazia Therapeutics Ltd (ASX:KZA) is a top-10 finalist in the Australia New Zealand Leadership Forum (ANZLF) Trans-Tasman Innovation and Growth Awards.

The awards are run by the ANZLF, which brings senior business and government leaders together to help Australia and New Zealand prosper in the global economy.

Innovative programs for brain and ovarian cancer

The company was recognised for its strong growth story and diverse and collaborative culture with its innovative programs for brain and ovarian cancer.

Four winners will receive a unique prize package that includes A$20,000 and an exclusive invite to the Accenture’s summit experiences in February and May 2020.

Other finalists include FarmBot Monitoring Solutions, RoboticsPlus, Whispli, Tectonus and AdAlta Ltd.

Late-stage clinical company

Kazia chief executive officer James Garner recently said attaining six clinical trials over the last 12 months showed Kazia had come a long way in a short time.

“Four of our studies are primarily funded by sources external to Kazia, either by the hospitals or by the US National Cancer Institute.

“This support creates enormous leverage for Kazia.”

Kazia is set to become a late-stage clinical company in 2020.

Quick facts: Kazia Therapeutics Ltd

Price: 0.94 AUD

Market: ASX
Market Cap: $67.84 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...


Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott following the news it's been awarded US Food and Drug Administration (FDA) Fast Track Designation (FTD) for Paxalisib for the treatment of glioblastoma – the most common and aggressive form...

on 08/21/2020

2 min read